Medical Aspects of Chemical Warfare (2008) - The Black Vault

Decontamination of Chemical Casualties51. Hanssen KA, Doxzon BF, Lumpkin HL, Clarkson E, Braue EH Jr. Evaluation of decontamination systems challengedwith nerve agents. In: Proceedings of the 25th Army Science Conference, 27–30 November 2006 [CD-ROM]. Arlington, Va:Assistant Secretary of the Army (Acquisition, Logistics and Technology); 2006. Paper KP-16.52. FDA clears skin lotion for military to protect against chemical burns [press release]. Washington, DC: US Food andDrug Administration; March 28, 2003.53. Sweeney R, Director, Government Contracting, O’Dell Engineering Ltd. Personal e-mail communication with BoardmanCH, 2004.54. Letter from the Food and Drug Administration to the US Army authorizing the marketing of RSDL in the UnitedStates, March 25, 2003, archived at Joint Program Executive Office for Chemical and Biological Defense, Falls Church,Va.55. US Departments of the Army, Marine Corps, Navy, and Air Force. Health Service Support in a Nuclear, Biological, andChemical Environment. Draft. Washington, DC: DoD; 2004. FM 4-02.7, MCRP 4-11.1F, NTTP 4-02.7, AFTTP (l) 3-2.47.56. Cooper GJ, Ryan JM, Galbraith KA. The surgical management in war of penetrating wounds contaminated withchemical warfare agents. J R Army Med Corps. 1994;140:113–118.57. Hobson D, Snider T. Evaluation of the Effects of Hypochlorite Solutions in the Decontamination of Wounds Exposed to Eitherthe Organophosphate Chemical Surety Material VX or the Vesicant Chemical Surety Material HD. Columbus, Ohio: BattelleMemorial Institute; 1992. Task 89-04.58. Graham JS, Research Biologist, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground,Md. Unpublished research.59. Lindsay RS. Swatch Test Results of Phase 2 Commercial Chemical Protective Gloves to Challenge by Chemical Warfare Agents:Executive Summary. Aberdeen Proving Ground, Md: Defense Technical Information Center; 2001. AD-A440407. Availableat: http://stinet.dtic.mil/cgi-bin/GetTRDoc?AD=ADA440407&Location=U2&doc=GetTRDoc.pdf. AccessedDecember 20, 2007.60. US Army Medical Research Institute of Chemical Defense. General Provisions for Neat Research Chemical Agent (NRCA).Aberdeen Proving Ground, Md: USAMRICD; 2006. SOP No. 96-124-RS-02.61. Smith W, PhD. US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Md. Personalcommunication with Charles Hurst, 1996.62. Horton DK, Berkowitz Z, Kaye WE. Secondary contamination of ED personnel from hazardous materials events,1995–2001. Am J Emerg Med. 2003;21:199–204.63. Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway sarin attack: disaster management, Part 2: Hospital response.Acad Emerg Med. 1998;5:618–624.64. Nozaki H, Hori S, Shinozawa Y, et al. Secondary exposure of medical staff to sarin vapor in the emergency room.Intensive Care Med. 1995;21:1032–1035.65. Foroutan A. Medical notes on the chemical warfare: part IX. Trans. Kowsar Med J. Fall 1997;2(3).66. World Health Organization. The impact of pesticides on health. Available at: http://www.who.int/mental_health/prevention/suicide/en/PesticidesHealth2.pdf. Accessed June 12, 2006.67. Stacey R, Morfey D, Payne S. Secondary contamination in organophosphate poisoning: analysis of an incident. Q J M.2004;97:75–80.68. Cox R. Hazmat. Emedicine [serial online]. Available at: http://www.emedicine.com/emerg/topic228.htm. AccessedAugust 17, 2005.555